Genolution Past Earnings Performance
Past criteria checks 0/6
Genolution's earnings have been declining at an average annual rate of -119%, while the Life Sciences industry saw earnings growing at 31.2% annually. Revenues have been declining at an average rate of 78.1% per year.
Key information
-119.0%
Earnings growth rate
-133.5%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | -78.1% |
| Return on equity | -5.0% |
| Net Margin | -41.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How Genolution makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 11,335 | -4,717 | 7,992 | 2,426 |
| 30 Jun 23 | 14,490 | -1,157 | 8,308 | 2,301 |
| 31 Mar 23 | 16,565 | 2,942 | 8,641 | 1,382 |
| 31 Dec 22 | 38,085 | 14,602 | 8,784 | 1,516 |
| 30 Sep 22 | 51,841 | 24,773 | 9,535 | 1,914 |
| 30 Jun 22 | 63,875 | 29,779 | 9,692 | 1,821 |
| 31 Mar 22 | 76,624 | 35,170 | 9,552 | 1,561 |
| 31 Dec 21 | 72,834 | 34,394 | 9,486 | 1,649 |
| 30 Sep 21 | 89,790 | 42,500 | 10,045 | 1,190 |
| 30 Jun 21 | 100,739 | 46,688 | 9,880 | 854 |
| 31 Mar 21 | 102,841 | 44,613 | 9,024 | 795 |
| 31 Dec 20 | 85,303 | 32,046 | 8,275 | 463 |
| 30 Sep 20 | 51,890 | 16,891 | 4,632 | 534 |
| 31 Dec 19 | 3,951 | -287 | 1,649 | 462 |
| 31 Dec 14 | 1,638 | -802 | 1,161 | 350 |
| 31 Dec 13 | 1,518 | -466 | 1,091 | 87 |
Quality Earnings: A225220 is currently unprofitable.
Growing Profit Margin: A225220 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A225220's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A225220's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A225220 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (18%).
Return on Equity
High ROE: A225220 has a negative Return on Equity (-4.97%), as it is currently unprofitable.